ClinicalTrials.gg
CompletedNCT01228734TAILORUpdated Jan 28, 2020Results posted

A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients

A Phase 3 interventional study of Cetuximab and Oxaliplatin in Metastatic Colorectal Cancer, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 25 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-28.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
553
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies testing cetuximab in Colorectal Neoplasms — 35 open to participants now, 43 under way, 7 of them phase 3. Cetuximab · Colorectal Neoplasms.

Enrollment
19th of 185
553 · median 60
Started
2010
with 11 others
Phase 3
29 of 187
5 open now
Registered
82nd of 187
by date
Lead sponsor
4 of 187
Merck KGaA, Darmstadt, Germany

Among the 187 studies testing cetuximab in Colorectal Neoplasms, this one is the 19th largest by enrollment of the 185 interventional ones that give a count, is one of 12 that started in 2010, is one of 29 in phase 3, and was the 82nd registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

35 of the 187 studies testing cetuximab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing cetuximab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study was to assess whether the progression free survival (PFS) time with FOLFOX-4 plus cetuximab is longer than that with FOLFOX-4 alone as first-line treatment for mCRC in Chinese subjects with RAS wild-type tumors.

03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • Metastatic colorectal cancer
  • RAS wild type
  • Cetuximab
  • First line treatment
  • First occurrence of metastatic colorectal cancer in Chinese subjects with RAS wildtype
  • status
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written (first and second)
  • Chinese with Chinese citizenship
  • Male or female subjects greater than or equal to (>=) 18 years of age
  • Medically accepted effective if procreative potential exists (applicable for both male and female subjects until at least 90 days after the last dose of trial treatment)
  • Diagnosis of confirmed adenocarcinoma of the colon or rectum
  • First occurrence of disease (not curatively resectable) RAS wild-type status in tumor tissue
  • At least one by computer tomography (CT) or magnetic resonance imaging (MRI) according to (not in an irradiated area)
  • of at least 12 weeks
  • (ECOG) performance status of 0 or 1 at trial entry
  • White blood cell count >= 3 × 10x9/L with neutrophils >= 1.5 × 10x9/L, count >= 100 × 10x9/L and >= 6.21 mmol/L (10 g/dL)
  • Total \<= 1.5 × upper limit of reference range
  • (AST) and alanine transaminase (ALT) \<= 2.5 × upper limit of reference range or \<= 5 × upper reference range in subjects with liver metastasis
  • Serum creatinine \<= 1.5 × upper limit of reference range
  • Recovery from relevant toxicity due to previous treatment before trial entry

Exclusion criteria

Exclusion Criteria:

  • Previous chemotherapy for CRC except treatment if terminated > 9 months (oxaliplatin-based chemotherapy) or > 6 months (non-oxaliplatin-based chemotherapy) before the start of treatment in this trial
  • Radiotherapy or surgery (excluding prior diagnostic ) in the 30 days before trial treatment
  • Previous treatment with monoclonal antibody therapy, vascular endothelial growth factor (VEGF) pathway-targeting therapy, epidermal growth factor receptor (EGFR) pathway-targeting therapy, or other signal transduction inhibitors
  • History of organ allograft, stem cell transplantation, or allogeneic stem cell transplantation
  • Renal replacement therapy
  • Intake of any medication within 30 days before trial entry
  • Concurrent chronic systemic immune therapy or hormone therapy except physiologic replacement
  • Granulocyte colony stimulating factor (G-CSF) or granulocyte macrophage colony stimulating factor (GM-CSF) within 3 weeks of trial entry (these growth factors may be used during the trial thereafter)
  • Other non-permitted concomitant anticancer therapies
  • Known and/or . Subjects with neurological symptoms should undergo a CT scan/MRI of the brain to exclude brain metastasis
  • Previous other than CRC in the last 5 years except basal cell cancer of the skin or preinvasive cancer of the cervix
  • cardiovascular disease, e.g. cardiac failure of classes III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial infarction in the last 5 years, or below the institutional range of normal on a baseline multiple gated acquisition scan or echocardiogram
  • Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease
  • Active clinically serious infections (> grade 2 National Cancer Institute- (NCI-CTCAE) version 3.0), including active tuberculosis
  • Known and declared history of (HIV) infection or chronic or C
  • Peripheral neuropathy > grade 1
  • Signs and symptoms suggestive of transmissible spongiform encephalopathy, or family members who suffer(ed) from such
  • Uncontrolled diabetes mellitus, pulmonary fibrosis, acute pulmonary disorder, interstitial pneumonia, or liver failure
  • Known or allergic reactions against any of the components of the trial treatments
  • Pregnancy (absence to be confirmed by serum β-human chorionic gonadotropin test) or breastfeeding
  • Ongoing alcohol or drug abuse
  • Presence of a medical or psychological condition that would not permit the subject to complete the trial or sign
  • Participation in another clinical trial within the past 30 days
  • Other significant disease that in the investigator's opinion should exclude the subject from the trial
  • Legal incapacity or limited legal capacity
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
553 participants (actual)

Study arms

  • Experimental
    Cetuximab + FOLFOX-4

    Subjects received cetuximab in combination with FOLFOX-4 chemotherapy regimen. FOLFOX-4 chemotherapy regimen consists of a combination of oxaliplatin with 5-fluorouracil (5-FU)/folinic acid (FA). Cetuximab was always administered every 7 days with an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions, followed by oxaliplatin 85 mg/m\^2 infused over 120 minutes at least 1 hour later. Following completion of the oxaliplatin infusion or simultaneously with oxaliplatin, FA was administered at a dose of 200 mg/m\^2 infused over 120 minutes, on Day 1, Day 2, and every 2 weeks and then 5- FU was administered as a bolus of 400 mg/m\^2/day intravenously over 2-4 minutes followed by 600 mg/m\^2/day infused over 22 hours, on Day 1, Day 2, and every 2 weeks. All subjects received treatment until progression of disease, withdrawal of consent, or unacceptable toxicity.

    Drug: Cetuximab · Drug: Oxaliplatin · Drug: Folinic Acid · Drug: 5Fluorouracil

  • Active comparator
    FOLFOX-4

    Subjects received FOLFOX-4 chemotherapy regimen that consists of a combination of oxaliplatin with 5-FU/FA. Oxaliplatin 85 mg/m\^2 infused over 120 minutes was administered first or simultaneously with FA at a dose of 200 mg/m\^2 infused over 120 minutes on Day 1, Day 2, and every 2 weeks and then 5-FU was administered as a bolus of 400 mg/m\^2/day intravenously over 2-4 minutes followed by 600 mg/m\^2/day infused over 22 hours on Day 1, Day 2, and every 2 weeks. All subjects received treatment until progression of disease, withdrawal of consent, or unacceptable toxicity.

    Drug: Oxaliplatin · Drug: Folinic Acid · Drug: 5Fluorouracil

Interventions

  • Cetuximab was administered every 7 days at an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity to cetuximab.

    Also known as: Erbitux, C225

  • Oxaliplatin 85 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.

  • FA 200 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.

  • 5-FU as a bolus of 400 mg/m\^2/day intravenously over 2-4 minutes followed by 600 mg/m\^2/day infusion over 22 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) Time

    PFS was defined as the duration (in months) from randomization until the first progressive disease (PD) observation as assessed by the Independent Review Committee (IRC) according to Response Evaluation Criteria for Solid Tumors (RECIST) version 1.0, or death due to any cause when death occurred within 90 days of randomization or the last tumor assessment, whichever was later. PD was defined as at least a 20% increase in the sum of longest diameter (LD) of the target lesions, taking as references the smallest sum LD since the treatment started (including baseline), or appearance of one or more new lesions, and/or unequivocal progression of existing non-target lesions.

    Time frame: Baseline up to 333 weeks

Secondary outcomes

  1. Overall Survival (OS) Time

    OS was defined as the time (in months) from randomization to death. For subjects who were still alive at the analysis data cut-off date or who lost to follow-up, survival was censored at the last recorded date that the subject was known to be alive.

    Time frame: Baseline up to 333 weeks

  2. Best Overall Response Rate (ORR)

    The Best ORR was defined as the percentage of subjects having achieved complete response (CR) or partial response (PR) according to RECIST version 1.0 as determined by the IRC. CR: defined as disappearance of all target and all non-target lesions and no new lesions. PR: defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters, no progression of non-target lesions and no new lesions.

    Time frame: Baseline up to 333 weeks

  3. Time to Treatment Failure (TTF)

    TTF was defined as time from randomization to date of the first occurrence of radiologically confirmed PD as determined by IRC, Clinical PD according to the Investigator's assessment (if radiological confirmation of PD by IRC was unavailable), discontinuation of treatment due to progression or adverse event, start of new anticancer therapy, withdrawal of consent, or death within 90 days of last tumor assessment or randomization. Subjects without event were censored on the date of last tumor assessment.

    Time frame: Baseline up to 333 weeks

  4. Number of Subjects With Curative Surgery of Liver Metastases

    The number of subjects who underwent liver metastatic surgery after start of treatment and the outcome of surgery with respect to residual tumor after surgery (R0, R1, R2, not evaluable) were summarized. In case of resection of more than one metastasis, the worst outcome of surgery defined the overall status of a subject. R0 = No residual tumor after resection (all lesions resected completely); R1 = Metastases not resected completely with microscopic residual lesions; and R2 = Metastases not resected completely with macroscopic residual lesions.

    Time frame: Baseline up to 333 weeks

07

Results

Posted Mar 6, 2017

Participant flow

The study was planned to enroll subjects with Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type (wt) tumors.Following modification of approved EU indication of cetuximab,a decision made to amend study population from subjects with KRAS wt tumors to those with RAS wt tumors. All efficacy/safety analysis based on subjects with RAS wt tumor.

Participant flow — Overall Study
MilestoneCetuximab + FOLFOX4FOLFOX4
Started193204
Modified intent-to-treat population193200
Modified safety population194199
Completed193200
Not completed04
Withdrew: Randomized, but not treated04

Outcome measures

PrimaryProgression Free Survival (PFS) Time

PFS was defined as the duration (in months) from randomization until the first progressive disease (PD) observation as assessed by the Independent Review Committee (IRC) according to Response Evaluation Criteria for Solid Tumors (RECIST) version 1.0, or death due to any cause when death occurred within 90 days of randomization or the last tumor assessment, whichever was later. PD was defined as at least a 20% increase in the sum of longest diameter (LD) of the target lesions, taking as references the smallest sum LD since the treatment started (including baseline), or appearance of one or more new lesions, and/or unequivocal progression of existing non-target lesions.

Time frame:
Baseline up to 333 weeks
Reported as:
Median · months
Progression Free Survival (PFS) Time
monthsCetuximab + FOLFOX-4FOLFOX-4
Progression Free Survival (PFS) Time9.2 (8.8 to 10.9)7.4 (5.8 to 7.5)
Statistical analysis
  • Cetuximab + FOLFOX-4 vs FOLFOX-4 · Log Rank · p = <0.001 · Hazard ratio (hr): 0.629 · 95% CI 0.498 to 0.794
SecondaryOverall Survival (OS) Time

OS was defined as the time (in months) from randomization to death. For subjects who were still alive at the analysis data cut-off date or who lost to follow-up, survival was censored at the last recorded date that the subject was known to be alive.

Time frame:
Baseline up to 333 weeks
Reported as:
Median · months
Overall Survival (OS) Time
monthsCetuximab + FOLFOX-4FOLFOX-4
Overall Survival (OS) Time20.8 (16.3 to 23.5)16.5 (14.8 to 19.5)
SecondaryBest Overall Response Rate (ORR)

The Best ORR was defined as the percentage of subjects having achieved complete response (CR) or partial response (PR) according to RECIST version 1.0 as determined by the IRC. CR: defined as disappearance of all target and all non-target lesions and no new lesions. PR: defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters, no progression of non-target lesions and no new lesions.

Time frame:
Baseline up to 333 weeks
Reported as:
Number · percentage of subjects
Best Overall Response Rate (ORR)
percentage of subjectsCetuximab + FOLFOX-4FOLFOX-4
Best Overall Response Rate (ORR)66.3 (59.2 to 72.9)40.5 (33.6 to 47.7)
SecondaryTime to Treatment Failure (TTF)

TTF was defined as time from randomization to date of the first occurrence of radiologically confirmed PD as determined by IRC, Clinical PD according to the Investigator's assessment (if radiological confirmation of PD by IRC was unavailable), discontinuation of treatment due to progression or adverse event, start of new anticancer therapy, withdrawal of consent, or death within 90 days of last tumor assessment or randomization. Subjects without event were censored on the date of last tumor assessment.

Time frame:
Baseline up to 333 weeks
Reported as:
Median · months
Time to Treatment Failure (TTF)
monthsCetuximab + FOLFOX-4FOLFOX-4
Time to Treatment Failure (TTF)9.2 (7.4 to 9.3)5.6 (5.6 to 6.5)
SecondaryNumber of Subjects With Curative Surgery of Liver Metastases

The number of subjects who underwent liver metastatic surgery after start of treatment and the outcome of surgery with respect to residual tumor after surgery (R0, R1, R2, not evaluable) were summarized. In case of resection of more than one metastasis, the worst outcome of surgery defined the overall status of a subject. R0 = No residual tumor after resection (all lesions resected completely); R1 = Metastases not resected completely with microscopic residual lesions; and R2 = Metastases not resected completely with macroscopic residual lesions.

Time frame:
Baseline up to 333 weeks
Reported as:
Number · subjects
Number of Subjects With Curative Surgery of Liver Metastases
subjectsCetuximab + FOLFOX-4FOLFOX-4
Subjects with liver surgery96
Subjects with liver surgery outcome: R072
Subjects with liver surgery outcome: R112
Subjects with liver surgery outcome: R200
Subjects not evaluable00

Adverse events

Collected over Baseline up to Safety Follow up (assessed up to 333 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cetuximab + FOLFOX-4157/194 (80.9%)42/194 (21.6%)194/194 (100%)
FOLFOX-4173/199 (86.9%)27/199 (13.6%)194/199 (97.5%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventCetuximab + FOLFOX-4FOLFOX-4
INTESTINAL OBSTRUCTIONGastrointestinal disorders7/1944/199
MULTI-ORGAN FAILUREGeneral disorders3/1943/199
HEPATIC FAILUREHepatobiliary disorders2/1940/199
DRUG HYPERSENSITIVITYImmune system disorders2/1941/199
URETERIC OBSTRUCTIONRenal and urinary disorders2/1940/199
DYSPNOEA AT RESTRespiratory, thoracic and mediastinal disorders2/1940/199
VENOUS THROMBOSIS LIMBVascular disorders2/1941/199
THROMBOCYTOPENIABlood and lymphatic system disorders0/1942/199
THROMBOCYTOPENIC PURPURABlood and lymphatic system disorders0/1942/199
CEREBRAL INFARCTIONNervous system disorders0/1942/199
Most frequent other events
Showing 10 of 59
Most frequent other events
EventCetuximab + FOLFOX-4FOLFOX-4
NEUTROPENIABlood and lymphatic system disorders156/194149/199
LEUKOPENIABlood and lymphatic system disorders151/194146/199
RASHSkin and subcutaneous tissue disorders120/1947/199
THROMBOCYTOPENIABlood and lymphatic system disorders92/194102/199
NAUSEAGastrointestinal disorders70/19492/199
FATIGUEGeneral disorders77/19456/199
DECREASED APPETITEMetabolism and nutrition disorders75/19460/199
DIARRHOEAGastrointestinal disorders69/19435/199
ALANINE AMINOTRANSFERASE INCREASEDInvestigations65/19454/199
HYPOKALAEMIAMetabolism and nutrition disorders65/19438/199

Baseline characteristics

Modified intent-to-treat (MITT) population included all subjects with RAS wild-type tumor status who were randomized to study treatment and who received at least 1 dose of study treatment. Subjects were analyzed as randomized.

Age, Continuous
Age, Continuous(years)Cetuximab + FOLFOX-4FOLFOX-4Total
Mean54.8 ± 11.855.1 ± 11.254.9 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Cetuximab + FOLFOX-4FOLFOX-4Total
Female6661127
Male127139266
08

Study locations

25 sites
  • Fujian Province Cancer Hospital
    Fuzhou, Fujian 350014, China
  • Fuzhou General Hospital
    Fuzhou, Fujian 350025, China
  • First Hospital Affiliated to Guangzhou University of Chinese Medicine
    Guangzhou, Guangdong 510405, China
  • Nanfang Hospital
    Guangzhou, Guangdong 510515, China
  • The Tumor Hospital of Harbin Medical University
    Harbin, Heilongjiang 150040, China
  • Union Hospital of Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei 430023, China
  • Jilin Cancer Hospital
    Changchun, Jilin 130012, China
  • First Affiliated Hospital of Jilin University
    Changchun, Jilin 130021, China
  • The Affiliated Hospital of Medical College Qingdao University
    Qingdao, Shandong 266003, China
  • The First Affiliated Hospital of College of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310009, China
  • Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310016, China
  • 307 Hospital of PLA
    Beijing, 100071, China
  • The General Hospital of the People's Liberation Army
    Beijing, 100853, China
  • Affiliated Hospital of Bengbu Medical College
    Bengbu, 233004, China
  • The Xiangya 2nd Hospital of Central South University
    Changsha, Hunan, 410011, China
  • Southwest Hospital
    Chongqing, 400038, China
  • Yunnan Provincial Tumor Hospital
    KunMing, Yunnan, 650118, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, 330006, China
  • Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, 200025, China
  • Fudan University Shanghai Cancer Center
    Shanghai, 200032, China
  • Shanghai First People's Hospital
    Shanghai, 200080, China
  • Fudan University Zhongshan Hospital
    Shanghai, China
  • The First Affiliated Hospital of Soochow University
    Shuzhou, Jiangsu, 215006, China
  • Tianjin People's Hospital
    Tianjin, 30000, China
  • Xijing Hospital the 4th Military Medical University of PLA
    Xi'an, 710032, China
09

References and documents

Publications

  • Wang H, Huang L, Gao P, Zhu Z, Ye W, Ding H, Fang L. Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial. BMJ Open. 2020 Feb 12;10(2):e030738. doi: 10.1136/bmjopen-2019-030738. PubMed 32051297 ↗
  • Bai L, Zhang P, Zhou K, Liao W, Li Q. Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer. Cancer Manag Res. 2019 Dec 12;11:10419-10426. doi: 10.2147/CMAR.S219318. eCollection 2019. PubMed 31849531 ↗
  • Qin S, Li J, Wang L, Xu J, Cheng Y, Bai Y, Li W, Xu N, Lin LZ, Wu Q, Li Y, Yang J, Pan H, Ouyang X, Qiu W, Wu K, Xiong J, Dai G, Liang H, Hu C, Zhang J, Tao M, Yao Q, Wang J, Chen J, Eggleton SP, Liu T. Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial. J Clin Oncol. 2018 Oct 20;36(30):3031-3039. doi: 10.1200/JCO.2018.78.3183. Epub 2018 Sep 10. PubMed 30199311 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2010 to primary completion in Jan 2016, 64 months.

Results were first posted in Mar 2017, 1 year 1 month after primary completion.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 64 months is above that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2010
First posted
Oct 26, 2010
StartActual
Sep 9, 2010
Primary completionActual
Jan 25, 2016
CompletionActual
Jan 31, 2018
Results first posted
Mar 6, 2017
Last update
Jan 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01228734
Responsible party
Sponsor
First posted
Oct 26, 2010
Start date
Sep 9, 2010
Primary completion
Jan 25, 2016
Completion
Jan 31, 2018
Results posted
Mar 6, 2017
Last update
Jan 28, 2020

Study contacts

Medical Responsible
study director · Merck Serono Co., Ltd., Beijing, an affiliate of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetuximab

Start the discussion